NCT07166185View on ClinicalTrials.gov

Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

70

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions

Non Metastatic HER2 Positive Breast Cancer

Trial Locations (1)

09000

RECRUITING

Medical oncology department - Anti Cancer Center of Blida, Blida

All Listed Sponsors

lead

Blida 1 University

OTHER